Search Results

There are 14840 results for: content related to: Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

  1. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study

    American Journal of Hematology

    Volume 90, Issue 4, April 2015, Pages: 314–319, María Victoria Mateos, Paul G. Richardson, Meletios A. Dimopoulos, Antonio Palumbo, Kenneth C. Anderson, Hongliang Shi, Jennifer Elliott, Edward Dow, Helgi van de Velde, Liviu Niculescu and Jesús F. San Miguel

    Article first published online : 27 FEB 2015, DOI: 10.1002/ajh.23933

  2. Effects of the proteasome inhibitor, bortezomib, on cytodifferentiation and mineralization of periodontal ligament cells

    Journal of Periodontal Research

    Volume 50, Issue 2, April 2015, Pages: 248–255, J. Kitagaki, S. Miyauchi, C. J Xie, M. Yamashita, S. Yamada, M. Kitamura and S. Murakami

    Article first published online : 20 JUN 2014, DOI: 10.1111/jre.12202

  3. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage

    Molecular Carcinogenesis

    Volume 52, Issue 2, February 2013, Pages: 118–133, Daniel R. Premkumar, Esther P. Jane, Naomi R. Agostino, Joseph D. DiDomenico and Ian F. Pollack

    Article first published online : 15 NOV 2011, DOI: 10.1002/mc.21835

  4. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

    American Journal of Hematology

    Volume 90, Issue 4, April 2015, Pages: E60–E65, Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Despina Kalapanida, Constantinos Pamboucas, Elisavet Kaldara, Argyrios Ntalianis, Erasmia Psimenou, Savvas T. Toumanidis, Anna Tasidou, Evangelos Terpos and Meletios A. Dimopoulos

    Article first published online : 9 MAR 2015, DOI: 10.1002/ajh.23936

  5. You have free access to this content
    Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma

    British Journal of Haematology

    Volume 168, Issue 1, January 2015, Pages: 55–62, Michelle Furtado, Rod Johnson, Anton Kruger, Deborah Turner and Simon Rule

    Article first published online : 22 AUG 2014, DOI: 10.1111/bjh.13101

  6. You have free access to this content
    Proteasome inhibition aggravates tumor necrosis factor–mediated bone resorption in a mouse model of inflammatory arthritis

    Arthritis & Rheumatism

    Volume 63, Issue 3, March 2011, Pages: 670–680, Karin Polzer, Kirsten Neubert, Silke Meister, Benjamin Frey, Wolfgang Baum, Jörg H. Distler, Eva Gückel, Georg Schett, Reinhard E. Voll and Jochen Zwerina

    Article first published online : 25 FEB 2011, DOI: 10.1002/art.30177

  7. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines

    International Journal of Laboratory Hematology

    Volume 34, Issue 3, June 2012, Pages: 237–247, B. ZHENG, R. ZHOU, Y. GONG, X. YANG and Q. SHAN

    Article first published online : 7 DEC 2011, DOI: 10.1111/j.1751-553X.2011.01384.x

  8. You have full text access to this Open Access content
    Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition

    Cancer Science

    Volume 101, Issue 6, June 2010, Pages: 1403–1408, Daisuke Tamura, Tokuzo Arao, Kaoru Tanaka, Hiroyasu Kaneda, Kazuko Matsumoto, Kanae Kudo, Keiichi Aomatsu, Yoshihiko Fujita, Takashi Watanabe, Nagahiro Saijo, Yoshikazu Kotani, Yoshihiro Nishimura and Kazuto Nishio

    Article first published online : 15 MAR 2010, DOI: 10.1111/j.1349-7006.2010.01544.x

  9. Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy

    Glia

    Volume 58, Issue 16, December 2010, Pages: 1961–1976, Yoon Kyung Shin, So Young Jang, Hyun Kyoung Lee, Junyang Jung, Duk Joon Suh, Su-Yeong Seo and Hwan Tae Park

    Article first published online : 9 SEP 2010, DOI: 10.1002/glia.21065

  10. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer

    International Journal of Cancer

    Volume 137, Issue 3, 1 August 2015, Pages: 686–697, Sonja Thaler, Gitta Thiede, Jan G. Hengstler, Arno Schad, Marcus Schmidt and Jonathan P. Sleeman

    Article first published online : 8 JAN 2015, DOI: 10.1002/ijc.29404

  11. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer

    Journal of Surgical Oncology

    Volume 105, Issue 4, 15 March 2012, Pages: 357–364, Annette Wunderlich, Tjadina Arndt, Melina Fischer, Silvia Roth, Annette Ramaswamy, Brandon H. Greene, Cornelia Brendel, Ulrike Hinterseher, Detlef K. Bartsch and Sebastian Hoffmann

    Article first published online : 17 OCT 2011, DOI: 10.1002/jso.22113

  12. You have free access to this content
    Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically

    BJU International

    Volume 109, Issue 8, April 2012, Pages: 1258–1268, Akinori Sato, Takako Asano, Keiichi Ito, Makoto Sumitomo and Tomohiko Asano

    Article first published online : 2 SEP 2011, DOI: 10.1111/j.1464-410X.2011.10533.x

  13. You have full text access to this Open Access content
    Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1

    Cancer Science

    Volume 100, Issue 2, February 2009, Pages: 341–348, Masaki Ri, Shinsuke Iida, Takashi Ishida, Asahi Ito, Hiroki Yano, Atsushi Inagaki, Jianmin Ding, Shigeru Kusumoto, Hirokazu Komatsu, Atae Utsunomiya and Ryuzo Ueda

    Article first published online : 5 DEC 2008, DOI: 10.1111/j.1349-7006.2008.01038.x

  14. You have free access to this content
    A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

    British Journal of Haematology

    Volume 127, Issue 2, October-II 2004, Pages: 165–172, S. Jagannath, B. Barlogie, J. Berenson, D. Siegel, D. Irwin, P. G. Richardson, R. Niesvizky, R. Alexanian, S. A. Limentani, M. Alsina, J. Adams, M. Kauffman, D.-L. Esseltine, D. P. Schenkein and K. C. Anderson

    Article first published online : 27 SEP 2004, DOI: 10.1111/j.1365-2141.2004.05188.x

  15. You have free access to this content
    Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma

    Cancer

    Volume 113, Issue 4, 15 August 2008, Pages: 765–771, John D. Hainsworth, David R. Spigel, John Barton, Cindy Farley, Marshall Schreeder, Jeremy Hon and F. Anthony Greco

    Article first published online : 9 JUN 2008, DOI: 10.1002/cncr.23606

  16. You have free access to this content
    The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib

    British Journal of Haematology

    Volume 161, Issue 1, April 2013, Pages: 43–56, Girija Dasmahapatra, Hiral Patel, Paul Dent, Richard I. Fisher, Jonathan Friedberg and Steven Grant

    Article first published online : 30 JAN 2013, DOI: 10.1111/bjh.12206

  17. Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish

    Journal of the Peripheral Nervous System

    Volume 17, Issue 1, March 2012, Pages: 76–89, Tahsin M. Khan, Nathan Benaich, Clare F. Malone, Rebecca L. Bernardos, Amy R. Russell, Gerald B. Downes, Michael J. Barresi and Lara D. Hutson

    Article first published online : 28 MAR 2012, DOI: 10.1111/j.1529-8027.2012.00371.x

  18. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)

    Pediatric Blood & Cancer

    Volume 60, Issue 3, March 2013, Pages: 390–395, Jodi A. Muscal, Patrick A. Thompson, Terzah M. Horton, Ashish M. Ingle, Charlotte H. Ahern, Renee M. McGovern, Joel M. Reid, Matthew M. Ames, Igor Espinoza-Delgado, Brenda J. Weigel and Susan M. Blaney

    Article first published online : 9 AUG 2012, DOI: 10.1002/pbc.24271

  19. You have free access to this content
    Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction

    British Journal of Haematology

    Volume 146, Issue 3, August 2009, Pages: 270–281, Tae Young Kim, Jongmin Park, Bora Oh, Hyun Jung Min, Tae-Sook Jeong, Jae Hoon Lee, Cheolwon Suh, June-Won Cheong, Hyo Jung Kim, Sung-Soo Yoon, Seung Bum Park, Dong Soon Lee and the Korean Multiple Myeloma Working Party (KMMWP)

    Article first published online : 3 JUN 2009, DOI: 10.1111/j.1365-2141.2009.07752.x

  20. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases

    European Journal of Haematology

    Volume 80, Issue 5, May 2008, Pages: 407–418, Pavani Srimatkandada, Regina Loomis, Rocco Carbone, Srinivasan Srimatkandada and Jill Lacy

    Article first published online : 23 JAN 2008, DOI: 10.1111/j.1600-0609.2008.01044.x